Resource Library

Adolescent Girls and Young Women Overcoming Adherence Challenges with Vaginal and Oral PrEP Use: A longitudinal qualitative study from a crossover trial in South Africa, Uganda, and Zimbabwe

This article from AIDS and Behavior explores South African, Ugandan, and Zimbabwean adolescent girls and young women’s experiences in a crossover trial of two HIV prevention products: daily oral PrEP and a monthly dapivirine vaginal ring.

Research, Service Delivery

HIV Rapid Diagnostic Test Market Landscape, 2023

This landscape analysis explores the HIV testing market to assess what factors can help preach global testing targets.

Demand Creation/Marketing, Testing

We Choose: Adolescent girls and young women’s choice for an HIV prevention product in a cross-over randomized clinical trial conducted in South Africa, Uganda, and Zimbabwe

This article from PLOS One describes decision-making and product choice amongst adolescent girls and young women in South Africa, Uganda, and Zimbabwe when given a choice between oral PrEP and the dapivirine vaginal ring as part of the REACH crossover study.

Research

“Killing Two Birds with One Stone” – A qualitative study on women’s perspectives on the dual prevention pill in Johannesburg, South Africa

This article from BMC Women’s Health describes the results of a study to investigate the acceptability of a dual prevention pill (DPP), combining oral PrEP and a combined oral contraceptive for HIV and pregnancy prevention, among women in Johannesburg, South Africa.

Research

Harnessing Private Sector Strategies for Family Planning to Deliver the Dual Prevention Pill, the First Multipurpose Prevention Technology with Pre-exposure Prophylaxis, in an Expanding HIV Prevention Landscape

This article from the Journal of the International AIDS Society describes the results of a scoping exercise to evaluate different private sector delivery channels for the Dual Prevention Pill in Kenya, South Africa, and Zimbabwe.

Research, Service Delivery

PURPOSE 1 Summary

This factsheet provides a summary of the PURPOSE 1 phase III clinical trial of lenacapavir for PrEP and F/TAF for cisgender women taking place in South Africa and Uganda.

Research

PEP FactSheet

This tool developed by the South Africa National Department of Health is intended to support clinical education efforts related to HIV PEP.

PEP Counseling Job Aid

This tool developed by the South Africa National Department of Health is intended to support health care providers in counseling their clients about PEP.

Clinical Algorithm for Initiation of HIV Post Exposure Prophylaxis (PEP) for HIV Prevention

This tool developed by the South Africa National Department of Health is intended to support health care providers in screening for PEP.

South Africa Strategic Direction Summary, 2023

Through the President’s Emergency Plan for AIDS Relief (PEPFAR) Country Operational Plan 2023 (COP23), the United States (US) government will support the Government of South Africa (GoSA) toward the shared goal of ending HIV as a public health threat by 2030. PEPFAR South Africa (PEPFARSA) is centering COP23 on the GoSA’s vision and strategy for…

Normative Guidance/Policies